Payment overview · 2025
General Payments
$653.57
29 reported records · 11 companies
Healthcare provider profile · identity verified
Agueda L Mercado, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1255360368
Verified facts
What the public records show
CMS Open Payments records show Agueda L Mercado, MD received $653.57 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $257.35 | 39.4% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $94.30 | 14.4% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $64.69 | 9.9% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $58.54 | 9.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.08 | 5.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $28.49 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.04 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.84 | 4.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.65 | 3.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.42 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.17 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $653.57 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $132.90 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $94.67 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $94.30 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $64.69 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $58.54 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.08 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $28.49 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.04 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 134 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
134 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
72 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 789 | 151 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 739 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 598 | 205 |
| Fluticasone Propionate | Fluticasone Propionate | 465 | 112 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 461 | 107 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 433 | 123 |
| Alendronate Sodium | Alendronate Sodium | 420 | 81 |
| Diclofenac Sodium | Diclofenac Sodium | 414 | 105 |
| Montelukast Sodium | Montelukast Sodium | 387 | 77 |
| Vascepa | Icosapent Ethyl | 371 | 100 |
| Metformin Hcl | Metformin Hcl | 359 | 98 |
| Meclizine Hcl | Meclizine Hcl | 350 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 301 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 73 |
| Januvia | Sitagliptin Phosphate | 241 | 46 |
| Ozempic | Semaglutide | 237 | 42 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 229 | 59 |
| Breo Ellipta | Fluticasone/Vilanterol | 224 | 48 |
| Ibuprofen | Ibuprofen | 198 | 60 |
| Glipizide | Glipizide | 196 | 47 |
| Ammonium Lactate | Ammonium Lactate | 185 | 40 |
| Azithromycin | Azithromycin | 182 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 167 | 57 |
| Ibandronate Sodium | Ibandronate Sodium | 164 | 30 |
| Linzess | Linaclotide | 160 | 36 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 160 | 128 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 159 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 45 |
| Single Use Swab | Alcohol Antiseptic Pads | 157 | 34 |
| Baclofen | Baclofen | 156 | 43 |
| Meloxicam | Meloxicam | 156 | 38 |
| Gabapentin | Gabapentin | 153 | 51 |
| Lisinopril | Lisinopril | 149 | 39 |
| Simvastatin | Simvastatin | 144 | 49 |
| Famotidine | Famotidine | 139 | 60 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 138 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 138 | 40 |
| Farxiga | Dapagliflozin Propanediol | 134 | 41 |
| Jardiance | Empagliflozin | 128 | 37 |
| Diclofenac Sodium Er | Diclofenac Sodium | 125 | suppressed |
| Losartan Potassium | Losartan Potassium | 125 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 41 |
| Mometasone Furoate | Mometasone Furoate | 112 | 32 |
| Celecoxib | Celecoxib | 94 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 93 | 18 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 86 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 25 |
| Naproxen | Naproxen | 84 | 21 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 81 | 36 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 80 | 31 |
| Doxepin Hcl | Doxepin Hcl | 74 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 72 | 31 |
| Trulicity | Dulaglutide | 72 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 25 |
| Ezetimibe | Ezetimibe | 69 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 69 | 15 |
| Carvedilol | Carvedilol | 68 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 66 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 18 |
| Valsartan | Valsartan | 65 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 64 | 18 |
| Eliquis | Apixaban | 62 | 21 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 61 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 16 |
| Procto-Med Hc | Hydrocortisone | 57 | 18 |
| Proctozone-Hc | Hydrocortisone | 54 | 11 |
| Entresto | Sacubitril/Valsartan | 53 | 14 |
| Nifedipine Er | Nifedipine | 51 | 18 |
| Ketoconazole | Ketoconazole | 49 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 15 |
| Fluocinonide | Fluocinonide | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | 16 |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 39 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 37 | 34 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 36 | 12 |
| Latanoprost | Latanoprost | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 33 | 19 |
| Hydrocortisone | Hydrocortisone | 33 | 11 |
| Memantine Hcl | Memantine Hcl | 32 | 11 |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Prednisone | Prednisone | 30 | 24 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | 15 |
| Diclofenac Potassium | Diclofenac Potassium | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Torsemide | Torsemide | 27 | 11 |
| Folic Acid | Folic Acid | 26 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Nabumetone | Nabumetone | 25 | suppressed |
| Ibu | Ibuprofen | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Finasteride | Finasteride | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 20 |
| Mupirocin | Mupirocin | 21 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Dexilant | Dexlansoprazole | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Terconazole | Terconazole | 14 | suppressed |
| Xiidra | Lifitegrast | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $653.57 · 29 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, FARXIGA, GARDASIL 9, IBSRELA, Kerendia, MOUNJARO, VOQUEZNA, Veozah, XIFAXAN, ZEPBOUND, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error